首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1831004

眼部過敏治療市場

Eye Allergy Treatment Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

預計眼部過敏治療市場將從 2024 年的 42.8 億美元成長到 2031 年的 59.3 億美元，2025 年至 2031 年的複合年成長率為 5.9%。

市場洞察與分析師觀點：眼部過敏治療包括非處方藥和處方藥，旨在緩解眼部發紅、搔癢、流淚和腫脹等症狀。常用產品包括抗組織胺眼藥水、肥大細胞穩定劑和合併療法。眼睛過敏的主要類型包括季節性或常年性過敏性結膜炎、春季角結膜炎、異位性角結膜炎和接觸性過敏性結膜炎。全球眼部過敏發生率的上升，以及非處方藥的普及，推動了眼部過敏治療市場的成長。

成長促進因素：眼部過敏，又稱為過敏性結膜炎，是由花粉、灰塵、寵物皮屑和黴菌等過敏原引發的。空氣污染加劇導致眼部過敏病例增加。此外，生活型態的改變、飲食習慣的改變、接觸過敏原的增加、螢幕使用時間的增加導致眼部疲勞，以及對眼部不適的敏感度增強，都導致全球人口眼部過敏反應顯著增加。

2020年發表的一項名為《過敏性結膜炎的當代視角》的研究表明，過敏性眼疾在北美普遍存在，影響著近40%的人口，而且這一數字還在持續上升。大約一半的美國眼部過敏症狀患者尋求藥物治療，但只有一小部分人使用處方藥，凸顯了新療法發展的潛力。

眼部過敏治療產品涵蓋用於控制和緩解眼部過敏相關症狀的產品。這些產品包括非處方藥和處方藥，用於緩解眼部發紅、搔癢、流淚和腫脹等症狀。常見產品包括抗組織胺眼藥水、肥大細胞穩定劑和非類固醇類抗發炎藥。眼部過敏患者數量的不斷成長推動了對治療方案的需求，從而推動了市場的成長。

眼部過敏治療市場的當前趨勢包括聯合療法的開發，預計未來將進一步促進市場成長。

戰略洞察

報告細分和範圍：透過研究治療類型、適應症、配銷通路和地理等不同細分市場，對眼部過敏治療市場進行了分析。治療領域包括藥物、過敏針劑和眼藥水。適應症領域分為季節性和常年性過敏性結膜炎、春季角結膜炎、特異性角結膜炎、接觸性過敏性結膜炎和巨乳頭狀結膜炎。分銷管道分為醫院藥局、線上藥局和藥局。

眼部過敏治療市場報告的範圍涵蓋北美（美國、加拿大和墨西哥）、歐洲（法國、德國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳洲和亞太其他地區）、中東和非洲（沙烏地阿拉伯、阿拉伯聯合大公國、南非和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地區）。

細分分析：眼部過敏治療市場依治療方法分為藥物、過敏注射劑和眼藥水。眼藥水細分市場在2022年佔據了相當大的市場佔有率，預計在2022-2030年期間的複合年成長率最高。

根據適應症，市場分為季節性和常年性過敏性結膜炎、春季角結膜炎、特異性角結膜炎、接觸性過敏性結膜炎和巨乳頭狀結膜炎。季節性和常年性過敏性結膜炎在2022年佔據了相當大的市場佔有率，預計在2022年至2030年期間將實現最高的複合年成長率。

就分銷管道而言，市場細分為醫院藥房、線上藥局和藥局。醫院藥局在2022年佔據了相當大的市場佔有率，而線上藥局預計將在2022-2030年期間實現最高的複合年成長率。

區域分析：眼部過敏治療市場報告主要按地理細分為北美、歐洲、亞太地區、南美和中美以及中東和非洲。 2022 年，北美佔據了相當大的市場佔有率，其中美國佔據主導地位。北美的成長歸功於先進的醫療基礎設施、主要市場參與者的強大影響力、眼睛過敏和乾眼症患者的增多以及創新藥物的推出。根據浸信會健康中心的數據，近 5,000 萬美國人患有某種形式的季節性過敏，約 30% 的成人和 40% 的兒童會出現影響眼睛、眼瞼和淚管的過敏反應。

乾眼症會導致眼部過敏，進而引發乾眼症。乾眼症在美國是一種常見但常被誤診的疾病。 2020年發布的美國國家健康與保健調查數據顯示，6.8%的美國成年人口被診斷為乾眼症。 2019年發表的一篇題為《墨西哥乾眼症患者眼表損傷的危險因子：一項基於人群的研究》的文章指出，近58%的墨西哥乾眼症患者主訴乾眼症。

製藥公司正在提升專業治療藥物（例如抗過敏眼藥水）的可及性，以擴大其在該地區市場的覆蓋範圍。自2022年3月起，艾爾建的LASTACAFT（0.25%阿卡他定滴眼液）已針對美國眼部過敏患者非處方箋銷售。隨著FDA近期批准其從處方藥轉為非處方藥，LASTACAFT的原始專利處方藥配方現已可在網上和銷售非處方眼藥水的零售店購買。這些因素正在推動該地區眼部過敏治療市場的成長。

眼部過敏治療市場報告範圍

產業發展與未來機會：全球眼部過敏治療市場參與者採取的幾項措施包括：

2020年9月，雷迪博士實驗室在美國市場推出了一款非處方眼部過敏眼藥水－鹽酸奧洛他定滴眼液，用於暫時緩解因花粉、草屑、動物毛髮和皮屑引起的眼部搔癢。 2020年2月，愛爾康公司獲得美國食品藥物管理局（FDA）批准，允許Pataday公司每日一次和每日兩次的眼部過敏瘙癢緩解配方在美國非處方銷售。 Pataday品牌採用領先的醫生處方眼部過敏瘙癢緩解成分，並包含首款無需處方即可獲得的每日一次的過敏瘙癢緩解滴眼液。

競爭格局和主要公司：眼部過敏治療市場的預測可以幫助利害關係人規劃其成長策略。市場的主要參與者包括博士倫、愛爾康、艾伯維、強生、Akorn Inc.、Nicox、參天製藥有限公司、梯瓦製藥工業有限公司、諾華公司和太陽製藥工業有限公司。這些公司專注於推出創新產品、增強現有產品並拓展地理範圍，以滿足全球日益成長的消費者需求。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與集中度

第 13 章：眼部過敏治療市場 - 主要公司簡介

Bausch and Lomb
Alcon
Johnson and Johnson Services Inc
AbbVie
Akorn Inc.
Nicox
Santen Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Novartis AG
Sun Pharmaceutical Industries Ltd.

第 14 章：附錄

簡介目錄

Product Code: TIPRE00007418

The eye allergy treatment market is anticipated to grow from US$ 4.28 billion in 2024 to US$ 5.93 billion by 2031, reflecting a CAGR of 5.9% from 2025 to 2031.

Market Insights and Analyst Perspective:Eye allergy treatments encompass both over-the-counter and prescription medications aimed at relieving symptoms such as redness, itching, tearing, and swelling of the eyes. Commonly utilized products include antihistamine eye drops, mast cell stabilizers, and combination therapies. The main types of eye allergies include seasonal or perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and contact allergic conjunctivitis. The rising incidence of eye allergies globally, along with the accessibility of over-the-counter treatments, supports the growth of the eye allergy treatment market.

Factors Driving Growth:Eye allergies, or allergic conjunctivitis, are triggered by allergens such as pollen, dust, pet dander, and mold. Increasing air pollution levels have led to a rise in eye allergy cases. Additionally, lifestyle changes, dietary habits, greater exposure to allergens, increased screen time causing eye strain, and heightened sensitivity to eye discomfort have all contributed to a significant increase in allergic reactions affecting the eyes among the global population.

A study titled "A Contemporary Look at Allergic Conjunctivitis," published in 2020, indicates that allergic eye disease is prevalent in North America, affecting nearly 40% of the population, a figure that continues to rise. Approximately half of the US population experiencing ocular allergy symptoms seek medication for relief, yet only a small percentage utilize prescription treatments, highlighting the potential for new treatment developments.

Eye allergy treatments consist of products designed to manage and alleviate symptoms associated with eye allergies. These include over-the-counter medications and prescription drugs that address symptoms like redness, itching, tearing, and swelling. Common products include antihistamine eye drops, mast cell stabilizers, and nonsteroidal anti-inflammatory drugs. The increasing number of individuals suffering from eye allergies drives the demand for treatment options, thereby propelling market growth.

Current trends in the eye allergy treatment market include the development of combination therapies, which are expected to further enhance market growth in the future.

Strategic Insights

Report Segmentation and Scope:The analysis of the eye allergy treatment market has been conducted by examining various segments: treatment type, indication, distribution channel, and geography. The treatment segment includes medication, allergy shots, and eye drops. The indication segment is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. Distribution channels are categorized into hospital pharmacies, online pharmacies, and drug stores.

The scope of the eye allergy treatment market report encompasses North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The eye allergy treatment market is categorized by treatment into medication, allergy shots, and eye drops. The eye drops segment accounted for a significant market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By indication, the market is divided into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment held a substantial market share in 2022 and is expected to register the highest CAGR from 2022 to 2030.

In terms of distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and drug stores. The hospital pharmacies segment held a significant market share in 2022, while the online pharmacy segment is anticipated to achieve the highest CAGR during 2022-2030.

Regional Analysis:The eye allergy treatment market report is primarily segmented by geography into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America held a significant market share in 2022, with the US leading the region. The growth in North America is attributed to the presence of advanced healthcare infrastructure, a strong presence of key market players, an increasing number of eye allergies and dry eye diseases, and the introduction of innovative medications. According to Baptist Health, nearly 50 million Americans suffer from some form of seasonal allergy, with about 30% of adults and 40% of children experiencing allergic reactions affecting their eyes, eyelids, and tear ducts.

Dry eye conditions can lead to eye allergies, which may subsequently result in dry eye disease. Dry eye disease is a common yet often underdiagnosed condition in the US. Data from the National Health and Wellness Survey published in 2020 indicated that 6.8% of the adult population in the US was diagnosed with dry eye. An article titled 'Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study,' published in 2019, reported that nearly 58% of individuals complained of dry eyes.

Pharmaceutical companies are enhancing access to specialized treatments, such as allergy-relieving eye drops, to broaden their market reach in the region. As of March 2022, Allergan's LASTACAFT (alcaftadine ophthalmic solution 0.25%) became available to Americans with ocular allergies without a prescription. Following the recent FDA approval for the switch from prescription to over-the-counter, the original patented prescription-strength formulation of LASTACAFT can now be found online and in retail stores where OTC eye drops are sold. These factors are driving the growth of the eye allergy treatment market in the region.

Eye Allergy Treatment Market Report Scope

Industry Developments and Future Opportunities:Several initiatives by market players in the global eye allergy treatment market include:

In September 2020, Dr Reddy's Laboratories launched an over-the-counter eye allergy drop, Olopatadine Hydrochloride Ophthalmic Solution, in the US market, indicated for temporary relief of itchy eyes due to pollen, grass, animal hair, and dander.In February 2020, Alcon received FDA approval for Pataday's once-daily and twice-daily relief formulations for over-the-counter sale in the US. The Pataday brand features the leading doctor-prescribed ingredient for eye allergy itch relief and includes the first once-daily allergy itch relief drop available without a prescription.

Competitive Landscape and Key Companies:The forecast for the eye allergy treatment market can assist stakeholders in planning their growth strategies. Key players in the market include Bausch + Lomb, Alcon, AbbVie, Johnson & Johnson, Akorn Inc., Nicox, Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, and Sun Pharmaceutical Industries Ltd. These companies are focused on launching innovative products, enhancing existing offerings, and expanding geographically to meet the increasing consumer demand globally.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Eye Allergy Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Eye Allergy Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Eye Allergy Treatment Market - Global Market Analysis

6.1 Eye Allergy Treatment - Global Market Overview
6.2 Eye Allergy Treatment - Global Market and Forecast to 2030

7. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2020-2030

7.1 Overview
7.2 Medication
7.3 Allergy Shots
7.4 Eye Drops

8. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Indication, 2020-2030

8.1 Overview
8.2 Seasonal and Perennial Allergic Conjunctivitis
8.3 Vernal keratoconjunctivitis
8.4 Atopic keratoconjunctivitis
8.5 Contact Allergic Conjunctivitis
8.6 Giant Papillary Conjunctivitis

9. Eye Allergy Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

9.1 Overview
9.2 Hospital Pharmacies
9.3 Online Pharmacy
9.4 Drug Stores

10. Eye Allergy Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

10.1 North America
- 10.1.1 North America Eye Allergy Treatment Market Overview
- 10.1.2 North America Eye Allergy Treatment Market Revenue and Forecasts to 2030
- 10.1.3 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Treatment
- 10.1.4 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Indication
- 10.1.5 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Eye Allergy Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Eye Allergy Treatment Market
    - 10.1.6.1.1 United States Eye Allergy Treatment Market, by Treatment
    - 10.1.6.1.2 United States Eye Allergy Treatment Market, by Indication
    - 10.1.6.1.3 United States Eye Allergy Treatment Market, by Distribution Channel
  - 10.1.6.2 Canada Eye Allergy Treatment Market
    - 10.1.6.2.1 Canada Eye Allergy Treatment Market, by Treatment
    - 10.1.6.2.2 Canada Eye Allergy Treatment Market, by Indication
    - 10.1.6.2.3 Canada Eye Allergy Treatment Market, by Distribution Channel
  - 10.1.6.3 Mexico Eye Allergy Treatment Market
    - 10.1.6.3.1 Mexico Eye Allergy Treatment Market, by Treatment
    - 10.1.6.3.2 Mexico Eye Allergy Treatment Market, by Indication
    - 10.1.6.3.3 Mexico Eye Allergy Treatment Market, by Distribution Channel
10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Eye Allergy Treatment Market - Key Company Profiles

13.1 Bausch and Lomb
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Alcon
13.3 Johnson and Johnson Services Inc
13.4 AbbVie
13.5 Akorn Inc.
13.6 Nicox
13.7 Santen Pharmaceutical Co. Ltd
13.8 Teva Pharmaceutical Industries Ltd
13.9 Novartis AG
13.10 Sun Pharmaceutical Industries Ltd.